Accessibility Menu
Coloplast A/s logo

Coloplast A/s(OTC) CLPBY

Market Cap$15.10BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)+27%
5 Year-53%
1 Year-22%
1 Month+8%
$7.09
-2.61%
-0.19Today
Coloplast A/s last closing stock price
MetricPriceDate
Last closeUSD 7.282026-09-03
Coloplast A/s stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.68%USD 7.162026-08-27
1 month+8.33%USD 6.722026-08-04
3 month+21.33%USD 6.002026-06-05
Year to date-13.33%USD 8.402025-12-31
1 year-22.13%USD 9.352025-09-03
3 year-29.69%USD 10.352023-09-01
5 year-52.77%USD 15.412021-09-03
Since inception+27.18%USD 5.722014-01-13

Coloplast A/s Financials at a Glance

Market Cap

$15.10BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

DKK 27.07B

Net Income (TTM)

DKK 2.76B

EPS (TTM)

$0.19

P/E Ratio

38.14

Dividend

$0.36

Beta (Volatility)

0.57 (Low)

Price

$7.09

Volume

53,338

Open

$7.08

Previous Close

$7.09

Daily Range

$7.08 - $7.15

52-Week Range

$5.64 - $10.03

Estimated Earnings Date

Nov 3, 2026

CLPBY News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Coloplast A/s

Coloplast A/S, founded in 1954 and headquartered in Humlebæk, Denmark, is a global leader in intimate healthcare products and services. The company operates in three primary segments: Chronic Care, Interventional Urology, and Wound & Skin Care, serving markets across Denmark, the United States, the United Kingdom, France, and beyond.

Products and Services
  • Advanced ostomy solutions, including the SenSura Mio and Brava accessories
  • Continence care products like SpeediCath catheters and Conveen Active urine bags
  • Innovative wound care dressings and a range of skin care items
Growth Outlook
  • Revenue of 7.48 billion DKK in Q3 2026, showing strong demand
  • Net income of 1.49 billion DKK in Q3 2026, indicating profitability
  • Consistent investment in R&D, enhancing product innovation and market reach
Financial Highlights
  • Trailing twelve month (TTM) revenue of 28.5 billion DKK, reflecting robust sales growth
  • Net profit margin of 9.71% TTM, showcasing effective cost management
  • Dividend yield of 5.04% TTM, appealing for income-focused investors
Coloplast A/S has established itself as a significant player in the healthcare sector, particularly in intimate care solutions. The company's diverse product offerings cater to a wide range of medical needs, ensuring a steady demand across its segments. Recent financial performance highlights a strong revenue trajectory, with Q3 2026 revenue reaching 7.48 billion DKK, supported by a net income of 1.49 billion DKK. This profitability underscores the company's operational efficiency and market positioning. The commitment to research and development is evident, as Coloplast continues to innovate and expand its product lines, which is crucial for maintaining competitive advantage in the healthcare market. The TTM revenue of 28.5 billion DKK and a net profit margin of 9.71% further illustrate the company's financial health and operational effectiveness. Additionally, the attractive dividend yield of 5.04% positions Coloplast as a compelling option for investors seeking both growth and income. Overall, Coloplast A/S presents a robust investment opportunity within the healthcare industry, driven by strong fundamentals and a clear growth strategy.
AI Generated • Aug 25, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

16,907

CEO

Gavin Wood, MBA

Website

www.coloplast.com

Headquarters

Humlebæk, ZE 3050, DK

CLPBY Financials

Key Financial Metrics (TTM)

Gross Margin

58.50%

Operating Margin

26.35%

Net Income Margin

9.71%

Return on Equity

19.69%

Return on Capital

18.38%

Return on Assets

5.89%

Earnings Yield

2.62%

Dividend Yield

4.94%

Payout Ratio

1.88%

Stock Overview

Market Cap

$15.10BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.07B

Volume

53.34K

Avg. Volume

306.54K

Financials (TTM)

Gross Profit

DKK 17.52B

Operating Income

DKK 7.53B

EBITDA

DKK 12.01B

Operating Cash Flow

DKK 7.74B

Capital Expenditure

-DKK 1.42B

Free Cash Flow

DKK 6.32B

Cash & ST Invst.

DKK 817.04M

Total Debt

DKK 23.80B

Coloplast A/s Performance Analysis

Coloplast A/s annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-09-30DKK 3,282,245,3135.2%
20232023-09-30DKK 3,507,139,8256.9%
20242024-09-30DKK 3,928,316,42412.0%
20252025-09-30DKK 4,124,716,4405.0%
Coloplast A/s sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-09-30-23.3%
Q12025-12-3131.9%
Q22026-03-312.3%
Q32026-06-303.9%
Coloplast A/s annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-09-30DKK 0.32-11.6%
20232023-09-30DKK 0.32-1.2%
20242024-09-30DKK 0.332.8%
20252025-09-30DKK 0.24-26.9%
Coloplast A/s sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-09-308.4%
Q12025-12-3158.7%
Q22026-03-31-171.3%
Q32026-06-30249.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

DKK 7.48B

+7.5%

Gross Profit

DKK 4.99B

+6.1%

Gross Margin

66.73%

N/A

Market Cap

$15.10BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$892.91K

N/A

Employees

16,907

N/A

Net Income

DKK 1.49B

+84.7%

EBITDA

DKK 2.31B

+6.0%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

DKK 817.04M

+12.5%

Total Debt

DKK 23.80B

-1.7%

Accounts Receivable

DKK 5.07B

-5.0%

Inventory

DKK 4.13B

+9.4%

Long Term Debt

DKK 20.93B

+21.1%

Short Term Debt

DKK 2.88B

-58.5%

Return on Assets

5.89%

N/A

Return on Invested Capital

18.61%

N/A

Free Cash Flow

DKK 1.49B

+22.9%

Operating Cash Flow

DKK 1.76B

+7.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SBHMYSino Biopharmaceutical Limited
$13.86+0.00%
SAUHYStraumann Holding AG
$11.53-1.66%
SUVPFSartorius AG
$270.29+0.00%
SAUHFStraumann Holding AG
$118.73+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.15-0.12%
NVDANvidia
$230.36+0.01%
PATHUiPath
$15.19-0.17%
INTCIntel
$95.80+0.05%

Questions About CLPBY

What is the current price of Coloplast A/s?

Coloplast A/s is trading at $7.09 per share.

What is the 52-week range for Coloplast A/s?

Over the past 52 weeks, Coloplast A/s has traded between $5.64 and $10.03.

How much debt does Coloplast A/s have?

As of the most recent reporting period, Coloplast A/s reported total debt of DKK 3.64B.

How much cash does Coloplast A/s have on hand?

Coloplast A/s reported DKK 124.96M in cash and cash equivalents in its most recent financial results.

What is Coloplast A/s’s dividend yield?

Coloplast A/s currently has a dividend yield of 4.94%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services